Delving into the Latest Updates on GSK2282512A with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, Multivalent vaccine

Synonyms

FLU-Q-QIV, Quadrivalent influenza vaccine

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Influenza, Human

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

GSK Plc

License Organization-

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.

The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49 years of age (YOA). In addition, this study will evaluate immunogenicity, safety and reactogenicity from co-administration of RSV MAT vaccine and GSK's quadrivalent seasonal influenza (Flu D-QIV) vaccine.

Start Date26 Oct 2021

Sponsor / Collaborator

GSK Plc

NCT01954251

/ CompletedPhase 3

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.

Start Date03 Oct 2013

Sponsor / Collaborator

GSK Plc

NCT01711736

/ CompletedPhase 3

Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children

The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new influenza vaccine GSK2282512A (FLU-Q-QIV) and compare its activity to the marketed vaccine Fluarix® (TIV) in young children 6 to 35 months of age.

Start Date01 Nov 2012

Sponsor / Collaborator

GSK Plc

100 Clinical Results associated with GSK2282512A

Login to view more data

100 Translational Medicine associated with GSK2282512A

Login to view more data

100 Patents (Medical) associated with GSK2282512A

Login to view more data

100 Deals associated with GSK2282512A

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Influenza, Human	Phase 3	Spain	GSK Plc	01 Oct 2010
Influenza, Human	Phase 3	Mexico	GSK Plc	01 Oct 2010
Influenza, Human	Phase 3	United States	GSK Plc	01 Oct 2010
Influenza, Human	Phase 3	Taiwan Province	GSK Plc	01 Oct 2010
Influenza, Human	Phase 3	Canada	GSK Plc	01 Oct 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05045144 (EudraCT, 2021-000357-26 \| ###DELETE, CTgov)	Phase 3	Respiratory Syncytial Virus Infections \| Influenza, Human	1,586	Flu Quadrivalent influenza vaccine (RSV+Flu Pooled Group)	(xquuzhcusd) = zugzmsvyrv gvaxzmfrkv (pffolqbnjw, hopizqsrpp - hkiugcnwlg) View more	-	05 Oct 2023
				Flu Quadrivalent influenza vaccine (15 μg HA) (Flu+Placebo Group)	(xquuzhcusd) = sihduzyhjm gvaxzmfrkv (pffolqbnjw, pjltoqngzk - ilkdakfsuw) View more
NCT01711736 (CTgov)	Phase 3	Influenza, Human	606	Quadrivalent influenza GSK2282512A vaccine (GSK2282512A Group)	dyuxusioig(sgqmkmtvfy) = wucfbmeqte gqwhbunkmc (vrifqumurs, oifevqdzvq - sauquvqpjd) View more	-	03 Apr 2014
				Fluarix (Fluarix Group)	(rfjubgonsd) = fvcpgfirud khnwjyquub (sbuwnewxrl, gsodupzndv - hkclqsyffh) View more
NCT01198756 (CTgov)	Phase 3	Influenza, Human	3,109	Quadrivalent seasonal influenza vaccine GSK2282512A (GSK2282512A 1 Group)	qtyeqttvzq(iymxfrzbmd) = drhuvjulhu litsluharn (psulmjgmyp, ezxfguhdtd - vlxrdmjxob) View more	-	12 Mar 2013
				Fluarix™ VB (Victoria Strain Fluarix Group)	qtyeqttvzq(iymxfrzbmd) = ycmbatnpll litsluharn (psulmjgmyp, nixjkvjpwe - cebaqtinxx) View more